WHO ICTRP trial
Reduced Toxicity and Reduced Intensity conditioning chemotherapy using…
CTRI/2020/09/027731 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2020/09/027731 |
|---|---|
| Public title | Reduced Toxicity and Reduced Intensity conditioning chemotherapy using Fludarabine and Treosulfan in allogenic bone marrow transplantation |
| Scientific title | Reduced Toxicity and Reduced Intensity conditioning regimen using Fludarabine and Treosulfan for high risk hematological malignancies undergoing allogenic hematopoietic cell transplantation - RIC FT-10 |
| Primary sponsor | Tata Medical Center |
| Secondary sponsors | Unrestricted research grant |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue |
| Interventions | Intervention1: Reduced toxicity, reduced intensity conditioning drug regimen : Fludarabine, 30mg/sq.m, days -6 to -2 Treosulfan, 10g/sq.m, days -6 to -4 Control Intervention1: NA: NA |
| Registration date | Oct 9, 2020 |
| Target size | 50 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: